231 related articles for article (PubMed ID: 26804020)
1. Hurdles to the introduction of new therapies for immune-mediated kidney diseases.
Anders HJ; Jayne DR; Rovin BH
Nat Rev Nephrol; 2016 Apr; 12(4):205-16. PubMed ID: 26804020
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal antibodies in nephrology: a delicate balance between curative potential, evidence of effectiveness, and toxicity].
Magistroni R
G Ital Nefrol; 2012; 29(3):283-91; discussion 292. PubMed ID: 22718451
[TBL] [Abstract][Full Text] [Related]
3. Biologics for the treatment of autoimmune renal diseases.
Holdsworth SR; Gan PY; Kitching AR
Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177
[TBL] [Abstract][Full Text] [Related]
4. [An innovative approach to the treatment of immune-mediated glomerular diseases].
Roccatello D
G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832439
[TBL] [Abstract][Full Text] [Related]
5. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
Cravedi P
G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
[TBL] [Abstract][Full Text] [Related]
6. Immunologic aspects of renal disease.
Ambrus JL; Sridhar NR
JAMA; 1997 Dec; 278(22):1938-45. PubMed ID: 9396656
[TBL] [Abstract][Full Text] [Related]
7. Plasma cells as an innovative target in autoimmune disease with renal manifestations.
Hiepe F; Radbruch A
Nat Rev Nephrol; 2016 Apr; 12(4):232-40. PubMed ID: 26923204
[TBL] [Abstract][Full Text] [Related]
8. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases.
Obligado SH; Ibraghimov-Beskrovnaya O; Zuk A; Meijer L; Nelson PJ
Kidney Int; 2008 Mar; 73(6):684-90. PubMed ID: 18094678
[TBL] [Abstract][Full Text] [Related]
9. Update on rituximab: an established treatment for all immune-mediated kidney diseases?
Evans R; Salama AD
Nephron Clin Pract; 2014; 126(3):97-109. PubMed ID: 24686110
[TBL] [Abstract][Full Text] [Related]
10. Can we personalize treatment for kidney diseases?
Rovin BH; McKinley AM; Birmingham DJ
Clin J Am Soc Nephrol; 2009 Oct; 4(10):1670-6. PubMed ID: 19808246
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of post-transplant glomerulonephritis].
Sandrini S; Valerio F
G Ital Nefrol; 2008; 25 Suppl 44():99-106. PubMed ID: 19048593
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lupus nephritis.
Austin HA; Boumpas DT
Semin Nephrol; 1996 Nov; 16(6):527-35. PubMed ID: 9125797
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and treatment of systemic lupus erythematosus nephritis.
Davidson A; Aranow C
Curr Opin Rheumatol; 2006 Sep; 18(5):468-75. PubMed ID: 16896284
[TBL] [Abstract][Full Text] [Related]
14. New biologics in the treatment of rare glomerular diseases of childhood.
Cravedi P; Angeletti A; Remuzzi G
Curr Opin Pharmacol; 2017 Apr; 33():27-33. PubMed ID: 28456094
[TBL] [Abstract][Full Text] [Related]
15. Update on the treatment of lupus nephritis.
Waldman M; Appel GB
Kidney Int; 2006 Oct; 70(8):1403-12. PubMed ID: 16929249
[TBL] [Abstract][Full Text] [Related]
16. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
Ferrari P; Frey FJ
Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
[TBL] [Abstract][Full Text] [Related]
17. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies.
Chalmers SA; Chitu V; Herlitz LC; Sahu R; Stanley ER; Putterman C
J Autoimmun; 2015 Feb; 57():42-52. PubMed ID: 25554644
[TBL] [Abstract][Full Text] [Related]
18. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases.
Meyrier A
Nephrol Dial Transplant; 1992; 7 Suppl 1():80-4. PubMed ID: 1337187
[No Abstract] [Full Text] [Related]
19. Lupus nephritis: from pathogenesis to targets for biologic treatment.
Liu Y; Anders HJ
Nephron Clin Pract; 2014; 128(3-4):224-31. PubMed ID: 25401461
[TBL] [Abstract][Full Text] [Related]
20. Membranous lupus nephritis.
Austin HA; Illei GG
Lupus; 2005; 14(1):65-71. PubMed ID: 15732291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
